News and Announcements
MedAdvisor Sees Strong Growth in Key Business Drivers
- Published June 29, 2016 9:39PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
29th June 2016, ASX Announcement
Highlights
- Strong progress across key revenue drivers for the business:
-Rapid acceleration in patient user growth, with approximately 18,000 patients now using the platform, a monthly growth rate of ~10% (vs. 6% in March Qtr.)
– Substantial pharmacy network expansion, with over 1,600 pharmacies now in the network, encompassing over 30% of all Australia’s community pharmacies
– The Company continues to grow its manufacturer client base for Patient Engagement Programs - Patients now ordering over $1 million worth of scripts refills each week through MedAdvisor pharmacies on our Tap-To-Refill script ordering function
- Increasing validation of the Company’s value proposition to patients, their pharmacies and the broader health system
To view the full announcement, please click on the button below.
Company Updates
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
Backed By Leading Investment Groups and Family Offices
